NDLI: Angiopoietins as serum biomarkers for lymphatic anomalies

Please wait, while we are loading the content...

Enhanced peripheral dopamine impairs post-ischemic healing by suppressing angiotensin receptor type 1 expression in endothelial cells and inhibiting angiogenesis

Differential regulation of angiogenic cellular processes and claudin-5 by histamine and VEGF via PI3K-signaling, transcription factor SNAI2 and interleukin-8

An extracellular proteasome releases endostatin from human collagen XVIII

An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure

A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named “normalization”

Angiopoietins as serum biomarkers for lymphatic anomalies

Aliskiren decreases oxidative stress and angiogenic markers in retinal pigment epithelium cells

Angiogenesis : Volume 19

Angiogenesis : Volume 18

Angiogenesis : Volume 17

Angiogenesis : Volume 16

Angiogenesis : Volume 15

Angiogenesis : Volume 14

Angiogenesis : Volume 13

Angiogenesis : Volume 12

Angiogenesis : Volume 11

Angiogenesis : Volume 10

Angiogenesis : Volume 9

Angiogenesis : Volume 8

Angiogenesis : Volume 7

Angiogenesis : Volume 6

Angiogenesis : Volume 5

Angiogenesis : Volume 4

Angiogenesis : Volume 3

Angiogenesis : Volume 2

Angiogenesis : Volume 1

Angiopoietins as serum biomarkers for lymphatic anomalies

Content Provider	Springer Nature Link
Author	Le Cras, Timothy D. Mobberley Schuman, Paula S. Broering, Mary Fei, Lin Trer, Cameron C. Adams, Denise M.
Copyright Year	2016
Abstract	Vascular anomalies can cause significant morbidity and mortality. Advances in diagnosis will be improved if noninvasive biomarkers can be identified, as obtaining a tissue biopsy can worsen the disease and precipitate complications. The goal of this study was to identify biomarkers for vascular anomaly patients to aid diagnosis and potentially give insights into pathogenesis. Blood was collected at baseline and then 6 and 12 months after treatment with the mTOR inhibitor sirolimus. Patients groups included generalized lymphatic anomaly (GLA), kaposiform lymphangiomatosis (KLA) and kaposiform hemangioendothelioma (KHE) with or without the Kasabach–Merritt phenomenon (KMP) coagulopathy. Serum was obtained from healthy controls selected to match the age and sex of the patients (21 days–28.5 years; 42% males; 58% females). Angiogenic and lymphangiogenic factors (VEGF-A, C, D, Ang-1 and Ang-2) were measured in serum using ELISA. In lymphatic anomaly patients, baseline levels of VEGF-A and VEGF-D were not different compared to controls. Angiopoietin-2 (Ang-2) levels were near controls levels in GLA patients but 10-fold greater in KLA patients and 14-fold greater in KHE patients when the KMP coagulopathy was present but not when it was absent. VEGF-C and angiopoietin-1 (Ang-1) levels were lower in KHE patients with KMP. Our analyses suggest that Ang-2 and Ang-1 can be used as biomarkers to help identify KLA and KHE patients with KMP coagulopathy with high sensitivity and specificity. After 12 months of sirolimus treatment, Ang-2 levels were lower in KLA and KHE with KMP patients compared to baseline levels and with most patients showing a clinical response. Hence, serum Ang-2 and Ang-1 levels may help in the diagnosis of patients with lymphatic anomalies and are concordant to sirolimus response.
Starting Page	163
Ending Page	173
Page Count	11
File Format	PDF
ISSN	09696970
Journal	Angiogenesis
Volume Number	20
Issue Number	1
e-ISSN	15737209
Language	English
Publisher	Springer Netherlands
Publisher Date	2016-12-18
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Vascular anomalies Generalized lymphatic anomaly Kaposiform lymphangiomatosis Kaposiform hemangioendothelioma Sirolimus Kasabach–Merritt Cancer Research Biomedicine Cell Biology Cardiology Ophthalmology Oncology
Content Type	Text
Resource Type	Article
Subject	Physiology Clinical Biochemistry Cancer Research

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Commentary: Transarterial Embolization in Neonatal Kasabach–Merritt Syndrome

Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies—Insights From a Retrospective Case Series

Kasabach-Merritt Phenomenon: Classic Presentation and Management Options

Case Report: Pancreatic and hepatic kaposiform hemangioendothelioma presenting as consumptive coagulopathy and right hepatic atrophy

Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma

Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis

Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics

Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!

Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.

Angiopoietins as serum biomarkers for lymphatic anomalies

Similar Documents

Commentary: Transarterial Embolization in Neonatal Kasabach–Merritt Syndrome

Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies—Insights From a Retrospective Case Series

Kasabach-Merritt Phenomenon: Classic Presentation and Management Options

Case Report: Pancreatic and hepatic kaposiform hemangioendothelioma presenting as consumptive coagulopathy and right hepatic atrophy

Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma

Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis

Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics

Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!

Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.

Angiopoietins as serum biomarkers for lymphatic anomalies